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Acute and chrome effects of thromboxane A2 inhibition on the renal
hemodynamics in streptozotocin-induced diabetic rats. We examined
acute and chronic effects of thromboxane (TX) A2 inhibition on the
renal hemodynamics at early and late stage of untreated streptozotocin
(STZ)-induced diabetic rats. Two weeks and 28 weeks after the induc-
tion of diabetes, renal blood flow (RBF) under anesthesia was measured
with an electromagnetic flowmeter before and after TXA2 inhibition. In
two-week-old diabetic rats, a specific TXA2 synthetase inhibitor, OKY-
046, or a specific TXA2 receptor antagonist, Sulotroban, increased renal
vascular resistance (RVR) and ameliorated the hyperperfusion. The
renal vasoconstrictive effect of OKY-046 was blunted by an angiotensin
converting enzyme (ACE) inhibitor, MK422, or an angiotensin II
receptor antagonist, Saralasin. On the contrary, OKY-046 ameliorated
the renal hypoperfusion by decreasing RVR in 28-week-old diabetic
rats. Chronic oral administration of OKY-046 ameliorated not only the
renal hyperperfusion but increased urinary albumin excretion (UAE) at
two weeks, but also the renal hypoperfusion, filtration fraction and
UAE at 24 weeks. It is suggested that TXA2 might, at least in part, play
important roles in the hyperperfusion by modulating activity of the
renin-angiotensin system at an early stage of untreated diabetic rats and
in the hypoperfusion at the late stage of untreated diabetic rats, and that
TXA2 is also involved in the increase of UAE. These results support
roles for TXA2 in the progression of renal injury in STZ-induced
diabetic rats.
It is well known that renal blood flow (RBF) and glomerular
filtration rate (GFR) increase in patients with newly diagnosed
insulin-dependent diabetes mellitus (IDDM) and in diabetic rats
with moderate hyperglycemia or with short-term severe hyper-
glycemia [1, 2]. The increases in RBF and GFR are considered
to be important factors in the development and the progression
of diabetic nephropathy [1, 2]. The mechanisms of hyperperfu-
sion and hyperfiltration, however, are still unknown. The roles
of prostaglandins (PGs) in the renal hemodynamic changes of
diabetes have been extensively studied [3—9]. Synthesis of
PGE2 and PG!2 in isolated glomeruli from diabetic rats with
moderate hyperglycemia and with short-term severe hypergly-
cemia is increased [3—6]. Administrations of non-steroidal anti-
inflammatory drugs ameliorate the renal hyperperfusion and the
glomerular hyperfiltration in IDDM patients [7] and in diabetic
rats [8, 9]. These data indicate that vasodilatory PGs are
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involved in renal and glomerular hemodynamic abnormalities in
diabetic subjects [1, 2, 10]. The role of thromboxane (TX) A2 in
diabetic nephropathy has also been investigated [3, 6, 11—161.
Urinary excretion of TXB2 increases in diabetic patients [11]
and diabetic rats [12—14]. Administration of TXA2 synthetase
inhibitors ameliorates microalbuminuria in IDDM patients [15,
16] and diabetic rats [14]. In diabetic rats with severe hypergly-
cemia for 2 months, there is enhanced intraglomerular TXA2
synthesis, resulting in a decreased GFR [6]. Glomerular syn-
thesis of TXA2 is also increased in four-week-old, severely
hyperglycemic diabetic rats, in which an administration of
TXA2 synthetase inhibitor enhances the hyperfiltration [3].
However, the role of TXA2 in diabetic renal hemodynamics
remains unclear. The aim of this study is to investigate the role
of TXA2 on the renal hemodynamics in untreated streptozoto-
cm (STZ)-induced diabetic rats.
Methods
Male Sprague-Dawley rats (Seiwa, Fukuoka, Japan) weighing
200 to 270 g were made diabetic by intraperitoneal injection of
STZ (90 mg/kg). Rats for normal control were given injection of
the vehicle alone; diabetic rats received no insulin. They were
allowed free access to water and a regular rat pellet diet (Na
0.12 mEq/g). Diabetic rats in which non-fasting blood glucose
levels were more than 300 mg/dl were studied.
The procedures for measuring RBF were as follows [17]. The
rats were maintained on a regular diet until 10 to 14 hours before
the experiment, at which time the food was removed and the
rats were allowed free access to water until the time of
anesthesia. The rats were anesthetized with mactin (80 mg/kg),
administered intraperitoneally. Rats were placed on a heat-
controlled table to maintain the rectal temperature at 37°C.
After tracheostomy was performed, PE-50 catheters were
placed in the right jugular vein and the left femoral artery, and
a PE-90 catheter was placed in the urinary bladder. Arterial
blood pressure was monitored continuously throughout the
experiments with a P231B Gould-Stathman pressure transducer
and recorded on a heat-writing recoder (WT-625G, Nihonko-
den, Tokyo, Japan). The left kidney was exposed through
abdominal incision, and the left renal artery was freed from the
surrounding tissues. The renal nerves were carefully avoided
during dissection and manipulation of the renal artery. The
arterial branches which did not enter into the kidney were
ligated. A flow probe (EP1O2, size 2 mm circular, Carolina
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Medical Electronics, King, North Carolina, USA) was placed
on the left renal artery. The probe was fixed on a flexible arm,
by which the position of the probe on the renal artery could be
stabilized. The abdomen was not closed around the probe and
the positioning of the probe was observed under microscopy
throughout the experiments. The flow probe was connected to
the flowmeter (Model FM5O1, Carolina Medical Electronics).
RBF was continuously monitored throughout the experiments
and recorded on the heat-writing recorder. Sixty minutes were
allowed after the surgery before any experimental procedures
or measurements were made. At the end of the experiments, the
zero flow line of RBF was verified by occlusion of the renal
artery distal to the probe. To replace the loss of fluid associated
with surgical preparations, 1% of body weight of rat plasma was
infused over 60 minutes, then followed by an infusion of rat
plasma at the rate of 0.2% of body wt/hr throughout the
experiments. Rat plasma obtained from normal rats was infused
into normal rats, and that obtained from diabetic rats was
infused into diabetic rats. Rats were also maintained on an
infusion of physiological saline at the rate of 2 mllhr during
surgical procedures, and at the rate of 1 nil/hr during the
experimental protocols. Preliminary study revealed that this
protocol maintained constant systemic hematocrit and arterial
pressure. RBF was measured every ten minutes during a basal
period of 30 minutes (control period), and during a subsequent
experimental period of 30 minutes (experimental period) that
commenced 30 minutes after starting an intravenous infusion of
the drugs. The coefficient of variation of the three measure-
ments of RBF during each period in normal control rats was
3.7%. RBF in normal control rats was stable for 120 minutes
after the 60 minute equilibration period (N = 5, 9.3 0.4
ml/min/g kidney wt after equilibration, 9.4 0.4 ml/min/g
kidney wt at 120 mm).
Experimental groups were as follows. All experiments in
series 1 and 2 were carried out two weeks after the injection of
STZ.
Series 1
The aim of this experiment was to evaluate the acute effects
of specific TXA2 inhibition on the renal hemodynamics in
normal and diabetic rats. In order to inhibit the activity of
TXA2, a specific TXA2 synthetase inhibitor, (E)-3-[4-(1-imida-
zolylmethyl)phenyl]-2-propenoic acid hydrochloride monohy-
drate (OKY-046, Ono Pharmaceuticals, Osaka, Japan) or a
specific TXA2 receptor antagonist, 4-[2-(benzene-sulfonamido)-
ethyl]-phenoxyacetic acid (BM13.177, Sulotroban, Yamanou-
chi Pharmaceuticals, Tokyo, Japan) was used. OKY-046 was
dissolved into physiological saline and administered at the rate
of 6 mg/kg/hr (1 ml/hr). Sulotroban was dissolved into 4.04%
1-arginine solution and administrated at the rate of 20 mg/kg/hr
(1 ml/hr). Four groups of rats were studied: N-OKY (N = 6),
normal control rats treated with OKY-046; DM-OKY (N = 10),
diabetic rats treated with OKY-046; DM-Sult (N = 8), diabetic
rats treated with Sulotroban; DM-C (N = 8), diabetic rats
treated with physiological saline (N = 4) or 4.04% 1-arginine
solution (N = 4). Because neither physiological saline nor
4.04% 1-arginine solution had any effect on renal hemodynam-
ics, the data were assembled into one group (DM-C). Sixty
minutes after the flow probe was placed on the left renal artery,
RBF was measured every ten minutes during a basal period of
30 minutes (control period) and during a subsequent experimen-
tal period of 30 minutes (experimental period) that commenced
30 minutes after starting an intravenous infusion of OKY-046,
Sulotroban or vehicles. Urine samples were collected into
plastic tubes during each period and frozen at —20°C until the
measurements of PGE2, 6-keto-PGF1a and TXB2. About 0.1 ml
of blood samples were collected from the left femoral artery at
the beginning and the end of each period, that is, the total blood
volume drawn was 0.4 ml in each rat, to determine hematocrits
and fasting blood glucose concentrations, and were replaced
with the same volume of physiological saline.
Series 2
The aim of this experiment was to evaluate the influence of an
angiotensin converting enzyme (ACE) inhibitor or an angioten-
sin II receptor antagonist on the acute effect of OKY-046 on
renal hemodynamics. Two groups of diabetic rats were studied
to evaluate the influence of an ACE inhibitor: DM-MK (N =9),
diabetic rats treated with the ACE inhibitor, MK422 (enalapri-
lat, Banyu Pharmceuticals, Tokyo, Japan); and DM-MK-OKY
(N = 10), diabetic rats treated with OKY-046 after the admin-
istration of MK422. In DM-MK, MK422 was dissolved into
physiological saline and administered at the rate of 1 mg/kg/hr (I
mllhr). Measurements of RBF and collections of urine and
blood samples were made on the same protocol as in series 1. In
DM-MK-OKY, the experiment was also performed on the same
protocol as in series 1, but the infusion of MK422 at the same
rate in DM-MK was initiated 30 minutes before the measure-
ment of the control period and continued throughout the
experiment. All values obtained in DM-MK-OKY group, there-
fore, were under the condition of ACE inhibition. Two other
groups of rats were studied to evaluate the influence of an
angiotensin II receptor antagonist on the effect of OKY-046 on
renal hemodynamics. An angiotensin II receptor antagonist,
Saralasin (Sigma, St. Louis, Missouri, USA), was used. Six
diabetic rats (DM-Sara-OKY) and four normal control rats
(N-Sara-OKY) were studied on the same protocol as in series 1.
After measurements in the control period, Saralasin at the rate
of 0.3 mg/kg/hr and OKY-046 at the same rate in DM-OKY
were initiated simultaneously and continued throughout the
experiment. Measurements of RBF in the experimental period
were performed after 30 minutes of equilibration. This dose of
Saralasin blocked the pressor response to an acute intravenous
bolus injection of angiotensin II sufficient to raise the mean
arterial pressure (MAP) by at least 25 mm Hg [17].
Series 3
To evaluate the acute effects of specific TXA2 inhibition on
the renal hemodynamics in long-term untreated diabetic rats,
renal hemodynamic study was performed in 28-week-old dia-
betic rats (N = 5) before and after the administration of
OKY-046 on the same protocol as in DM-OKY group. They
received no insulin and were allowed free access to water and a
regular rat pellet diet for 28 weeks.
Series 4
The effects of chronic TXA2 inhibition on the progression of
diabetic renal abnormalities were evaluated. Three groups of
rats were studied: DM-T (N = 12), diabetic rats treated with
OKY-046 in the drinking water (80 mg/kg/day) for six months;
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Table 1. Body weight (body wt), left kidney weight (kidney wt), fasting blood glucose concentration (FBS), hematocrit (Hct), and mean
arterial pressure (MAP) in each group in series 1 and 2
N
Body wt Kidney wt
FBS mgfdl
Hct % MAP mm Hg
cont. exper.cont. exper.g
Series 1
N-OKY 5 239 4" 1.1 0.03 98 7 43.8 0.7 43,4 1.3 110 4 111 4
DM-C 8 243 11b 1.4 0.18 333 10a,b 45.6 1.48 45.5 1.5 112 4" 114 3
DM-OKY 10 251 11b 1.4 0.058 262 22a,t, 47.2 0.78 46.5 0.6 109 3" 110 2
DM-Sult 8 247 9" 1.5 o.Ia 291 l98, 50.2 07a,c,d 49.8 0.8 108 2b lii 2
Series 2
DM-MK 9 270 8 1.5 0,18,b 264 19a,b 49.2 08a,c,d 491 0.8 118 2 116 I
DM-MK-OKY 10 260 I2 1.5 01a,b 250 l98t 50.6 05a,c,d 50.1± 0.6 110 2" 112 2
DM-Sara-OKY 6 269 10 1.5 0.078) 232 27a,b 50.6 05ac,d 50.1 0.6 110 2b,e 112 2
N-Sara-OKY 4 296 25 1.2 0.1 98 6 49.1 0.7cI 47.7 0.5 124 6 119 4
Values are expressed as means SEM. Abbreviations are: N, number of rats; cont., control period; exper., experimental period.
Treatment regimen abbreviations are: N-OKY, age-matched normal rats treated with thromboxane synthetase inhibitor (TSI); DM-C,
2-week-old diabetic rats treated with vehicles; DM-OKY, 2-old week diabetic rats treated with TSI; DM-Sult, 2-old week diabetic rats treated with
TXA2 receptor antagonist (TR); DM-MK, 2-week-old diabetic rats treated with ACE inhibitor; DM-MK-OKY, 2-week-old diabetic rats treated
with TSI and ACE inhibitor; DM-Sara-OKY, 2-week-old diabetic rats treated with TSL and angiotensin II receptor antagonist (AR); N-Sara-OKY,
age-matched normal rats treated with TSI and AR.
a P < 0.05 vs. N-OKYb P < 0.05 vs. N-Sara-OKY
P < 0.05 vs. DM-Cd p < 0.05 vs. DM-OKY
< 0.05 vs. DM-MK
P < 0.05 vs. respective control period
DM (N = 10), diabetic rats treated with vehicle alone; Normal(N = 8), age-matched normal rats treated with vehicle alone.
Diabetic rats received no insulin. OKY-046 was dissolved into
distilled water and prepared every two days. Water intake was
measured every two weeks and the concentration of OKY-046
was adjusted. OKY-046 was initiated three days after the
induction of diabetes. Fed blood glucose concentration and
body weight were also measured every two weeks. Twenty-
four-hour urine collections were performed at 2, 4, 8, 12, and 24
weeks after the initiation of OKY-046 treatment to measure
urinary albumin excretion (UAE), urinary TXB2 excretion, and
urinary 6-keto-PGF1a excretion. Measurements of RBF and
inulin clearance (GFR) were performed 2 and 24 weeks after the
initiation of OKY-046 treatment. Surgical procedures and fluid
replacements were the same as those in series 1, but physio-
logical saline and 2% inulin solution, dissolved into physiolog-
ical saline, were infused at a rate of 1 mllhr during the
experiment. Sixty minutes after surgery, three 15-minute timed
urine collections were performed and 0.1 ml of blood samples
were collected at the midpoint of urine collection. RBF was
measured every 15 minutes.
Analytical procedures
Renal vascular resistance (RVR) and filtration fraction (FF)
were calculated as follows: RVR = MAP/RBF, FF = GFRJ
RBF(1-Hct). Blood glucose concentration was determined with
glucose oxydase method. Inulin concentration was measured
with photometry by use of a cysteine-tryptophan reaction [45]
in order to avoid the influence of the chromogens, such as
glucose. Coefficient of variation at our laboratory was less than
5%. Urinary albumin concentration was determined by en-
zyme-linked immunosorbent assay (Ono Pharmaceuticals). Uri-
nary PGE2, 6-keto- PGF,,8 and TXB2 were extracted as follows
[11]. The urine samples were acidified to pH 3.0 with 1 N HCI,
and ethanol was added to 15% (vol/vol). The alliquots were
applied onto the ODS-silica columns (SEP-PAK C18 cartridge,
Waters Associates, Milford, Massachusetts, USA) and eluted
with 10 ml of 15% ethanol followed by 10 ml of distilled water,
20% chloroform and n-hexane. PGs and TXs absorbed to the
column were eluted with 10 ml of methylformate, collected, and
dried under a stream of nitrogen gas. This fraction was recon-
stituted in 1 ml of phosphate-buffered saline solution (pH 7.3)
and then PGE2, 6-keto-PGF1,8 and TXB2 in the reconstituted
fraction were measured by radioimmunoassy with specific
antisera (anti-PGE2: Amersham Japan, Tokyo, Japan; anti-6-
keto-PGF1,, and anti-TXB2: Ono Pharmaceuticals). The per-
centage of recovery calculated by using radioactive PGE2,
6-keto-PGF1 and TXB2 (Ono Pharmaceuticals) was almost
90%.
Statistical analysis
In every rat all values obtained during each period were
averaged, and the paired Student's 1-test was carried out
comparing the mean values of the control periods to subsequent
experimental periods. Differences among groups were deter-
mined by one-way analysis of varience (one-way ANOVA). All
values are reported as means SEM. P values of <0.05 were
considered to be statistically significant.
Results
Body weight, left kidney weight, fasting blood glucose con-
centration (FBS), hematocnt (Hct) and mean arterial pressure
(MAP) in each group in series 1 and 2 are shown in Table 1.
All diabetic rats gained body weight. Body weights were not
different among the diabetic groups. The kidney weight in
each diabetic group was significantly greater than that in normal
rats. Non-fasting blood glucose concentration on the day
before the experiment was 441 83 mgldl in all of the
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Table 2. Changes in renal blood flow (RBF) and renal vascular
resistance (RVR) in each group in series I and 2
RBF mi/mm RVRmm Hg/mi/mm
cont, exper. cont. exper.
Series I
N-OKY
DM-C
DM-OKY
DM-Sult
Series 2
DM-MK
DM-MK-OKY
DM-Sara-OKY
N-Sara-OKY
8.4 0.4
11.0 0.8
11.8 0.6a
11.7 0.3a
11.8 0.5a
13.3 07a,b
11.9 0.8a
10.6 0.7
8.9 0.5
11.1 0.8
10.3 0.6c
11.1 0.4c
12.2 0.5
12.9 0.7
11.8 0.7
10.6 0.7
13.2 0.8
10.7 0.8
9.5 0,6
9.3 0,3a
10.2 o.5a
8.5 0.5
9.7 o.5a
11.9 1.0
12.5 1.0
10.6 0.8
11.0 0.8c
9.9 0.4c
9.9 0.5
8.7 0.5
9.7 0.5
11.5 1.0
Values are expressed as means SEM.
a P < 0.05 vs. N-OKY
b P < 0.05 vs. N-Sara-OKY
P < 0.05 vs. respective control period
Abbreviations and treatment regimen abbreviations are in Table 1.
diabetic rats. Ten to 14 hours fasting reduced blood glucose
concentrations, but hyperglycemia was still observed in each
diabetic group. None of the diabetic rats had ketonuria after 10
to 14 hours of fasting. Initial Hcts in DM-Sult, DM-MK,
DM-MK-OKY, DM-Sara-OKY and N-Sara-OKY were higher
than those in N-OKY, DM-C and DM-OKY, but the Hct in
each group were stable throughout the experiment. Initial MAP
in N-Sara-OKY was higher than those in other groups except
DM-MK and DM-Sara-OKY. MAP in all groups except
DM-MK was unchanged throughout the experiment. In DM-
MK, MAP was slightly decreased after the administration of
MK422.
RBF and RVR in series 1 and 2 are shown in Table 2. Diabetic
rats had significantly higher RBF and lower RVR than normal
rats in the control period. RBF and RVR in the control period
were not different among diabetic groups.
Series 1
The acute effects of specific TXA2 inhibition on the renal
hemodynamics were studied in normal and two-week-old dia-
betic rats. RBF and RVR were not changed after the adminis-
tration of a specific TXA2 synthetase inhibitor, OKY-046, in
normal control rats (N-OKY). In diabetic rats, the administra-
tion of OKY-046 significantly decreased RBF and increased
RVR (DM-OKY). A specific TXA2 receptor antagonist, Su-
lotroban, also decreased RBF and increased RVR slightly but
significantly (DM-Sult). Both OKY-046 and Sulotroban, how-
ever, did not completely restore RBF and RVR to the normal
control values. OKY-046 decreased RBF from 140% to 116% of
normal control value, and Sulotroban decreased RBF from
139% to 124%. The administration of vehicle alone did not
cause any change in RBF and RVR in normal control rats
(Methods) and diabetic rats (DM-C).
Series 2
The influence of ACE inhibition or angiotensin II receptor
blockade on the acute effect of OKY-046 on the renal hemody-
namics was examined in two-week-old diabetic rats. The ad-
ministration of ACE inhibitor, MK422, alone did not cause any
change in RBF and RVR. In DM-MK-OKY, in which the
infusion of OKY-046 was initiated 60 minutes after starting the
continuous infusion of MK422, the administration of OKY-046
did not cause any decrease of RBF or any increase of RVR, as
was observed in DM-OKY. In addition, the simultaneous
infusion of Saralasin with OKY-046 (DM-Sara-OKY) blunted
the renal vasoconstrictive effect of OKY-046 observed in DM-
OKY. Simultaneous infusion of Saralasin with OKY-046 did not
affect the renal hemodynamics in normal control rats (N-Sara-
OKY).
The changes in RBF (d-RBF) and in RVR (d-RVR) after the
administration of vehicles, OKY-046, Sulotroban, MK422
+OKY-046 or Saralasin+OKY-046 in two-week-old diabetic
rats are shown in Figures 1 and 2. d-RBF and d-RVR after the
administration of OKY-046 or Sulotroban were significantly
larger than those after the administration of vehicles. d-RBF
and d-RVR after the administration of MK422+OKY-046 or
Saralasin+OKY-046 were significantly smaller than those after
the administration of OKY-046, and were not different from
those after the administration of vehicles.
Urinary excretion rates of TXB2, PGE2 and 6-keto-PGF1, in
DM-OKY, DM-Sult, DM-MK and DM-MK-OKY are shown in
Table 3. In DM-OKY, the urinary excretion rate of TXB2 was
significantly decreased after the administration of OKY-046,
but those of PGE2 and 6-keto-PGF1, were not changed. Su-
lotroban and MK422 did not affect the urinary excretion rates of
TXB2 and PGE2. In DM-MK-OKY, the urinary excretion rate
of TXB2 was significantly decreased but that of PGE2 was not
changed.
Series 3
The acute effects of specific TXA, inhibition on the renal
hemodynamics in 28-week-old diabetic rats were studied. The
fed blood glucose concentrations were more than 400 mgldl and
they had no ketonuria. Body weight was gradually increased
but significantly lower than that in age-matched normal control
rats at 28 weeks (diabetic, 316 12; normal, 548 11 g; P <
0.01). Left kidney weight in diabetic rats was larger than that in
normal control rats (diabetic, 2,3 0.1; normal, 1.8 0.1 g; P
<0.01). Table 4 shows Hct, MAP, RBF, and RVR before and
after the administration of OKY-046. Hct and MAP were
unchanged during the renal hemodynamic study. The adminis-
tration of OKY-046 significantly increased RBF and decreased
RVR, as opposed to the results observed in two-week-old
diabetic rats (Table 2, DM-OKY), but OKY-046 did not com-
pletely restore RBF and RVR.
Series 4
The effects of long-term TXA2 inhibition on the progression
of renal abnormalities in diabetic rats were examined. The data
were summarized in Table 5. In the diabetic groups, fed blood
glucose concentrations were more than 400 mg/dl and ketonuria
was not detected during six months. They gradually gained
body weight. The body weight and left kidney weight in the
diabetic groups were not different between the groups but
significantly different from those in normal rats. MAP at 2
weeks and 24 weeks was not different among three groups.
Urinary excretions of TXB2 and PGFI in non-treated diabetic
rats (DM group) were significantly increased both at 2 and 24
weeks. Chronic administration of OKY-046 in DM-T group
specifically decreased urinary TXB2 excretion.
3bI Fig 1. Changes in renal blood flow (d-RBF)
after infusion of vehicle, OKY-046,
Sulotroban, MK422+OKY-046, and
Saralasin+OKY-046 in 2-week-old diabetic
rats. d-RBF after infusion of OKY-046 or
Sulotroban was larger than that after infusion
of vehicles. d-RBF after infusion of
MK422+OKY-046 or Saralasin+OKY-046
was significantly smaller than that after
infusion of OKY-046 but not different from
Vehicle OKY-046 Sultroban MK422 Saralasin+ that after infusion of vehicle. (a) P < 0.05 vs.
+QKY-046 OKY-046 vehicle; (b) P < 0.05 vs. OKY.
2
4ia
a
I Fig 2. Changes in renal vascular resistance(d-RVR) after infusion of vehicle, OKY-046,
_______
Sulotroban, MK422+OKY-046, and Sarala-
sin+OKY-046 in 2-week-old diabetic rats. d-
RVR after infusion of OKY-046 or Sulotroban
was larger than that after infusion of vehicles.
d-RVR after infusion of MK422+OKY-046, or
Saralasin+OKY-046 was significantly smaller
than that after infusion of OKY-046 but not
different from that after infusion of vehicle.
Vehicle OKY-046 Sultroban MK422 Saralasin+ (a) P < 0.05 vs. vehicle; (b) P < 0.05 vs.
+OKY-046 OKY-046 OKY.
N
TXB2 pg/mm PGE2 pg/mm 6-keto-PGF1a pg/mm
cont, exper. cont. exper. cont. exper.
DM-OKY 5 58.5 5.6 33.6 7.2a 44.6 5.4 31.5 7.6 62 13.0 136 23.8
DM-Sult 5 63.6 12.3 45.9 8.5 43.7 43.6 43.6 8.8 ND ND
DM-MK 4 49.6 8.6 37.0 4.5 70.6 10.4 51.5 16.4 102 16.9 79 4.5
DM-MK-OKY 3 39.8 5.8 18.4 3.2a 97.9 20.9 71.4 11.0 ND ND
Values are expressed as means SEM. ND is not done. See Table 1 for abbreviations.
a P < 0.01 vs. respective control period
At two weeks, DM group showed hyperperfusion, hyperfil-
tration, and increased UAE, compared with normal rats. RBF
and RVR in DM-T were completely restored to those in normal
rats. Although GFR in DM-T was slightly lower and FF was
slightly higher than those in DM group, these differences were
not statistically significant. UAE in DM-T was significantly
lower than that in DM group but still higher than that in normal
rats.
At 24 weeks, the DM group showed hypoperfusion and
normal glomerular filtration rate, so that FF was significantly
higher than that in normal rats. Chronic administration of
OKY-046 in DM-T group ameliorated the hypoperfusion by
decreasing RVR. GFR in DM-T was slightly lower than that in
DM group. FF in DM-T group was completely restored to the
normal control value. UAE in DM-T group was remarkably
lower than that in DM group.
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Table 3. Changes in urinary excretion of TXB2, POE2, 6-keto-PGF1,,, in each group in series 1 and 2
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Table 4. Effects of acute administration of TXA2 synthetase
inhibitor, OKY-046, on renal hemodynamics in 28-week-old
diabetic rats
Hct MAP RBF RVR
Control period 50.5 1.1 112 4 9.3 0.8 12.5 1.3
Experimental period 50.0 1.3 114 2 10.2 0,7a 11.5 l.o
Values are expressed as means SEM. See Tables 1 and 2 for
abbreviations.
a P < 0.05 vs. control period
Discussion
In this study, untreated diabetic rats at two weeks after the
induction of diabetes showed renal hyperperfusion, hyperfiltra-
tion and normal FF, whereas the diabetic rats at 24 weeks
showed hypoperfusion, normal GFR and increased FF. These
data were consistent with previous findings [18—21]. Since MAP
is stable, it is suggested that RVR is a major factor in the
changes of RBF.
The new findings of this study were that an administration of
specific TXA2 synthetase inhibitor, OKY-046, or specific TXA2
receptor antagonist, Sulotroban, increased RVR and amelio-
rated the hyperperfusion at the early stage (2 weeks) of un-
treated diabetic rats, whereas OKY-046 decreased RVR and
ameliorated the renal hypoperfusion at the late stage (24 to 28
weeks) of untreated diabetic rats. In addition, it is also new that
the renal vasoconstrictive effect of OKY-046 at the early stage
of untreated diabetic rats was blunted under the condition of
renin-angiotensin blockade. Three lines of evidence suggest
that the changes in renal hemodynamics after administration of
OKY-046 or Sulotroban in early untreated diabetic rats are
most likely related to the specific inhibition of TXA2 activity.
First, RBF and RVR in DM-C, which served as the time-
controls, were unchanged throughout the experiment. Second,
the observation that urinary excretions of PGE2 and 6-keto-
PGF1 were unchanged in spite of the significant decreases of
urinary excretion of TXB2 in DM-OKY and DM-MK-OKY
indicated that OKY-046 selectively inhibited TXA2 synthetase.
Third, the TXA2/PGE2 receptor antagonist, Sulotroban, also
increased RVR and decreased RBF in diabetic rats, indicating
that POE2 was not involved in the renal vasoconstriction. To
our knowledge, Sulotroban has no agonistic actions at the dose
used in this study. Our preliminary study demonstrated that the
dose of Sulotroban used in this study was enough to inhibit the
vasoconstriction caused by TXA2 mimetic, U46619 (data not
shown). It was not likely that the renal vasoconstrictive effect
was secondary to the changes of MAP, since neither OKY-046
nor Sulotroban affected MAP. It is therefore suggested that the
specific TXA2 inhibition causes renal vasoconstriction at the
early stage, but causes renal vasodilation at the late stage of
untreated diabetic rats.
The renal vasoconstrictive effect of OKY-046 in early un-
treated diabetic rats blunted under the condition of ACE
inhibition. ACE inhibitors may potentiate the activity of brady-
kinin and increase the production of vasodilatory PGs. MK422
did not affect the urinary excretions of 6-keto-PGF1a and POE2
in this study. It has been reported that MK422 may have some
effects on kininase activity, but blockade of the renin-angioten-
sin system accounts for a significant part of the effects of
MK422 [22]. In addition, the fact that Saralasin also blunted the
renal vasoconstrictive effects of OKY-046 at the early stage of
diabetic rats indicated that angiotensin II was involved in the
mechanisms of renal vasoconstriction. These findings indicate
that OKY-046 may affect the renal hemodynamics at the early
stage of diabetic rats through mediation of the renin-angiotensin
system. It is suggested that increased TXA2 at the early stage of
untreated diabetic rats might contribute to the hyperperfusion
through the mechanism in which increased TXA2 causes the
relative suppression of angiotensin II activity. However, other
factors, such as vasodilatory PGs [3—9] and atrial natnuretic
peptide [23, 24], also contribute to the hyperperfusion, because
the complete reversal of diabetic hyperperfusion was not
achieved by TXA2 synthetase inhibition or TXA2 receptor
blockade in this study.
The relationships between TXA2 and renin-angiotensin sys-
tem have been reported by some investigators [25—27]. In
diabetic patients, the furosemide stimulated increase of plasma
renin activity (PRA) is less than that in normal subjects, and
there is a significant negative correlation between PRA and
urinary TXB2/6-keto-PGF1a ratio, suggesting that relatively
increased TXA2 could be a factor in the lower response in PRA
[25]. Welch, Wilcox and Dunbar [26] clearly demonstrated that
PRA was increased by the administration of TXA2 synthetase
inhibitor or TXA2 receptor antagonist and was decreased by
TXA2 mimetic in anesthetized normal rats, and that a rise in
PRA with TXA2 antagonist was not clearly related to changes in
salt balance, blood pressure or GFR. Omoto et al [27] reported
that intraperitoneal administration of OKY-046 augumented
renal cortical renin release and increased PRA in untreated
STZ-induced diabetic rats. Our preliminary study revealed that
the diabetic rats which were treated with oral administration of
OKY-046 (80 mg/kg/day) for two weeks had lower RBF and
higher PRA than untreated diabetic rats (RBF: 8.3 0.3 vs.
11.7 0.6 ml/min, P < 0.01; PRA: 4.5 0.2 vs. 3.6 0.4
ng/ml/hr; 0.1 <P < 0.05, respectively, N = 5 in each group). It
is therefore suggested that the inhibition of TXA2 activity at the
early stage of diabetic rats must cause the enhancement of
angiotensin II activity, of which the vasoconstrictive effect on
renal vascular beds could surpass the vasodilatory effect caused
by the TXA2 inhibition itself, resulting in the amelioration of
hyperperfusion.
The role of TXA2 on renal hemodynamics in normal and
pathologic conditions has been investigated [28, 29]. TXA2
appears to be of little importance in the maintenance of renal
function under physiological conditions, since the inhibition of
TXA2 does not alter GFR or RBF [28, 29]. Our results that
OKY-046 did not affect renal hemodynamics in normal control
rats confirmed the previous reports [28, 29]. However, Welch
and Wilcox reported that the TXA2 synthetase inhibitor, CGS-
13080, but not the TXA2 receptor antagonist, SQ-29548, re-
duced the clearance of p-aminohippurate (PAH) in normal
control rats [30]. Tucker et al demonstrated that TXA2 syn-
thetase inhibitor, Dazmegrel, decreased single nephron plasma
flow and nephron filtration rate in normal control rats. They
suggested that other vasoactive agents might participate during
TXA2 synthetase inhibitor infusion [31]. We do not have any
explanation of this discrepancy in normal rat.
Increased renal TXA2 production has been documented in
various renal diseases, such as nephrotoxic serum nephritis,
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Table 5. Effects of chronic administration of TXA2 synthetase inhibitor, OKY-046, on renal hemodynamics and urinary albumin excretion in
diabetic rats
N Body wt Kidney wt MAP RBF RVR
2 weeks
Normal 3 303 8 1.26 0.03 104 7 6.9 0.6 18,4 2.2
DM 5 244 20 1.34 0.02a 113 2 8.7 0.5a 13.1 0.6
DM-T 6 243 9 1.50 0.09a 115 3 5.7 0.4c 20.8 0.2c
24 weeks
Normal 5 548 11 1.8 0.01 120 7 7.8 0.8 15.5 0.4
DM 5 316 12b.e 2.3 o.Ioa,c 112 4 4.2 04b,e 27.9 22b.e
DM-T 6 319 l6 2.3 o.loa,e 112 3 5.5 O.l 20.7 0.6
Values are expressed as means SEM.
a P < 0.05 vs. respective Normal
b P < 0.01 vs. respective Normal
P < 0.05 vs. respective DM
d P < 0.01 vs. respective DM
e P < 0.01 vs. 2 week DM
Abbreviations are: N, numbers of rats; Body wt, body weight (g); Kidney wt, left kidney weight (g); RBF, renal blood flow (ml/minlg . kidney
wt); RVR, renal vascular resistance (mm Hg/ml/min/g kidney wt); GFR, glomerular filtration rate (mllmin/g. kidney wt); FF, filtration fraction;
UAE, urinary albumin excretion (mg/day); U-TXB2, urinary TXB2 excretion (ng/day); U-6keto-PGF1a, urinary 6-keto-PGF1a excretion (ng/day).
Treatment regimen abbreviations are: DM, diabetic rats treated with vehicle; DM-T, diabetic rats treated with TXA2 synthetase inhibitor,
OKY-046 (80 mg/kg/day).
Table 5. Continued
GFR FF UAE U-TXB2 U-6keto-PGF1
2 weeks
Normal 1.03 0.13 0.30 0.02 0.15 0.03 6.1 0.7 19.1 3.3
DM 1.41 0.27a 0.33 0.07 0.55 O.O8 14.2 3,3a 411.1 649b
DM-T 1.26 0.11 0.44 0,05 0.33 O.04 6.4 0.5C 475.8 35,2b
24 weeks
Normal 0.92 0.4 0.20 0.03 0.86 0.49 7.6 1.5 18.3 2.4
DM 1.07 0.12e 0.46 O.O4 23.5 65b,e 333 147b,e 747.6 130,5b
DM-T 0.70 0.IC 0.22 0.02C 3.72 l.O4 4.1 O.6 676.3
cyclosporine nephropathy, renal allograft rejection and ureteral
obstraction, and pharmacological inhibition of TXA2 synthesis
or TXA2 receptor increase RBF and GFR [28, 291. The effects
of TXA2 inhibition on renal hemodynamic abnormalities in
diabetes have also been reported by some investigators [3, 6,
16, 32]. Renal plasma flow, but not GFR, increases after an
administrarion of TXA2 inhibitor in IDDM patients [16]. Craven
et a! [3, 6] reported that the administration of selective TXA2
synthetase inhibitor enhanced hyperfiltration at four weeks and
prevented the decline in GFR at eight weeks in untreated
diabetic rats. An administration of TXA2 receptor antagonist,
SK&F96 184, increases RBF, GFR and single nephron GFR in
insulin-treated diabetic rats [32]. These findings suggest that
increased TXA2 in diabetes might serve as a simple vasocon-
strictor designed to lower GFR and RBF. The results in this
study that the acute and chronic TXA2 inhibition caused renal
vasodilatation at the late stage of diabetic rats are consistent
with the previous findings. However, the results that the acute
and chronic inhibition of TXA2 caused renal vasoconstriction in
two-week-old untreated diabetic rats contradict the previous
reports [3, 6, 16, 32]. Tucker et at recently demonstrated that
TXA2 synthetase inhibitor, Dazmegrel, caused renal vasocon-
striction in 7- to 10-day-old insulin-untreated diabetic rats [311
and in 70- to 100-day-old diabetic rats treated with small doses
of insulin [33], which is consistent with our findings in 2-week-
old diabetic rats. The discrepancy between our results in
2-week-old diabetic rats and previous reports [3, 6, 32] might
depend on the difference of the time when the experiments were
performed. Renal hyperperfusion has been demonstrated at two
weeks but not after four weeks in untreated diabetic rats [1, 2,
34—37], suggesting that the mechanisms responsible for renal
hemodynamic abnormalities after four weeks might be different
from those at two weeks. The responsiveness of vascular beds
to angiotensin II is also different between early and late diabetic
animals. The renal hemodynamic responses to exogenous or
endogenous angiotensin II at early stages (1 to 2 weeks) of
untreated diabetic rats are similar to [36, 38] or one half of those
observed in normal rats [36, 39], while renal and aortic respon-
siveness to exogenous angiotensin II at late stage (4 to 12
weeks) of untreated diabetic rats are markedly diminished [39,
40]. Taking these observations into consideration, it is sug-
gested that TXA2 inhibition at the late stage could not result in
an increase of RVR because of the diminished responsiveness
to angiotensin II in renal vasculature, even if TXA2 inhibition
might enhance angiotensin II activity. TXA2 inhibition at late
stage, therefore, might simply cause the inhibition of the
vasoconstrictive property of TXA2 itself. The finding in this
study that the acute administration of OKY-046 in 28-week-old
untreated diabetic rats increased RBF and decreased RVR,
reversed from the results in 2-week-old diabetic rats, supports
the hypothesis. Insulin treatment might influence the effect of
TXA2 inhibition on diabetic renal hemodynamics. TXA2 inhi-
bition increases RBF in the early stage [32] but decreases RBF
in the late stage [331 of insulin-treated diabetic rats. In contrast,
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TXA2 inhibition decreased RBF in the early stage but increased
RBF in the late stage of insulin-untreated diabetic rats in this
study. These paradoxical findings suggest that the duration of
diabetes and insulin treatment are important considerations.
Chronic administration of OKY-046 significantly decreased
UAE both at 2 weeks and 24 weeks, although it did not affect
the kidney weight. Since OKY-046 ameliorated the hyperper-
fusion and slightly decreased GFR in 2-week-old diabetic rats,
these renal hemodynamic changes might, at least partly, con-
tribute to the decrease of UAE. Other factors, such as glomer-
ular permeability, might also be involved in the decrease of
UAE. In 24-week-old diabetic rats treated with OKY-046, the
complete normalization of FF resulting from the improvement
of the renal hypoperfusion by OKY-046 was observed. It has
been reported that chronic administration of TXA2 synthetase
inhibitor prevented the glomerular basement membrane thick-
ening [12], and the increases in glomerular volume and mesan-
gial volume [41]. It is, therefore, suggested that both the
ameliorations in the renal hemodynamic abnormalities and in
the pathological changes caused by OKY-046 contribute to the
decrease in UAE observed at the early and late stages of
diabetic rats in this study.
In summary, the TXA2 inhibition ameliorated not only the
renal hyperperfusion at early stage but also the renal hypoper-
fusion at late stage of untreated diabetic rats. The effect of
TXA2 inhibition observed at the early stage of the diabetic rats
was blunted by ACE inhibition or angiotensin II receptor
blockade. It is suggested that TXA2 might, at least in part, play
an important role in the hyperperfusion by modulating the
activity of the renin-angiotensin system at an early stage and
also in the hypoperfusion at the late stage of untreated diabetic
rats. In addition, the TXA2 inhibition prevented the increase of
UAE both at early and at late stages of untreated diabetic rats.
These data support roles for TXA2 in the progression of renal
injury in STZ-induced diabetic rats. The specific mechanism by
which the inhibition of TXA2 enhances renin-angiotensin activ-
ity is not apparent in this study. Further studies are required to
clarify this issue.
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